Mistarz A, Winkler M, Battaglia S, Liu S, Hutson A, Rokita H
Mol Ther Oncolytics. 2023; 28:230-248.
PMID: 36875325
PMC: 9982455.
DOI: 10.1016/j.omto.2023.02.002.
Sementino E, Kadariya Y, Cheung M, Menges C, Tan Y, Kukuyan A
Mol Cancer Res. 2022; 20(5):699-711.
PMID: 35082167
PMC: 9081258.
DOI: 10.1158/1541-7786.MCR-21-0837.
Yu C, Niu X, Du Y, Chen Y, Liu X, Xu L
Cancer Immunol Immunother. 2019; 69(1):115-126.
PMID: 31802182
PMC: 11027837.
DOI: 10.1007/s00262-019-02445-2.
Fukui S, Nagasaka K, Miyagawa Y, Kikuchi-Koike R, Kawata Y, Kanda R
Oncotarget. 2019; 10(57):5932-5948.
PMID: 31666925
PMC: 6800272.
DOI: 10.18632/oncotarget.27219.
Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker W
Expert Opin Ther Targets. 2018; 22(8):675-686.
PMID: 29999426
PMC: 6300140.
DOI: 10.1080/14728222.2018.1498845.
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
Do T, Hirst J, Hyter S, Roby K, Godwin A
Oncotarget. 2017; 8(31):50376-50392.
PMID: 28881569
PMC: 5584138.
DOI: 10.18632/oncotarget.18970.
VSV based virotherapy in ovarian cancer: the past, the present and …future?.
Orzechowska B, Jedryka M, Zwolinska K, Matkowski R
J Cancer. 2017; 8(12):2369-2383.
PMID: 28819441
PMC: 5560156.
DOI: 10.7150/jca.19473.
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G, Stepanova D, Dubyk C, Handorf E, Deyev S, Lazar A
Oncogene. 2017; 36(38):5421-5431.
PMID: 28534510
PMC: 5608634.
DOI: 10.1038/onc.2017.143.
In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.
Canese R, Mezzanzanica D, Bagnoli M, Indraccolo S, Canevari S, Podo F
Front Oncol. 2016; 6:164.
PMID: 27446810
PMC: 4923069.
DOI: 10.3389/fonc.2016.00164.
Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.
Ayyagari V, Johnston N, Brard L
Anticancer Drugs. 2016; 27(6):547-59.
PMID: 27058706
PMC: 5053334.
DOI: 10.1097/CAD.0000000000000364.
Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model.
Gomez-Roman N, McGregor F, Wheate N, Plumb J
J Ovarian Res. 2015; 8:62.
PMID: 26384969
PMC: 4575495.
DOI: 10.1186/s13048-015-0189-4.
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Salaun M, Peng J, Hensley H, Roder N, Flieder D, Houlle-Crepin S
PLoS One. 2015; 10(7):e0132960.
PMID: 26193700
PMC: 4508003.
DOI: 10.1371/journal.pone.0132960.
Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G, Xiao F, OBrien S, Gabbasov R, Maglaty M, Xu R
Mol Cancer Ther. 2015; 14(4):1035-47.
PMID: 25646015
PMC: 4394029.
DOI: 10.1158/1535-7163.MCT-14-0800.
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H, Xiao F, Serebriiskii I, OBrien S, Maglaty M, Astsaturov I
Clin Cancer Res. 2013; 19(18):5053-67.
PMID: 23900136
PMC: 3778161.
DOI: 10.1158/1078-0432.CCR-13-1115.
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Do T, Xiao F, Bickel L, Klein-Szanto A, Pathak H, Hua X
Oncogene. 2013; 33(5):539-49.
PMID: 23334327
PMC: 3640671.
DOI: 10.1038/onc.2012.632.
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Ward K, Tancioni I, Lawson C, Miller N, Jean C, Chen X
Clin Exp Metastasis. 2013; 30(5):579-94.
PMID: 23275034
PMC: 3622195.
DOI: 10.1007/s10585-012-9562-5.
Technical challenges and limitations of current mouse models of ovarian cancer.
Garson K, Gamwell L, Pitre E, Vanderhyden B
J Ovarian Res. 2012; 5(1):39.
PMID: 23190474
PMC: 3537528.
DOI: 10.1186/1757-2215-5-39.
Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice.
Hensley H, Roder N, OBrien S, Bickel L, Xiao F, Litwin S
Neoplasia. 2012; 14(6):451-62.
PMID: 22787427
PMC: 3394188.
DOI: 10.1596/neo.12480.
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.
Tang H, Beer L, Chang-Wong T, Hammond R, Gimotty P, Coukos G
J Proteome Res. 2011; 11(2):678-91.
PMID: 22032327
PMC: 3272104.
DOI: 10.1021/pr200603h.
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R, Hu T, Rehemtulla A, Fearon E, Cho K
Clin Cancer Res. 2011; 17(23):7359-72.
PMID: 21903772
PMC: 3229658.
DOI: 10.1158/1078-0432.CCR-11-1388.